> top > docs > PMC:7253235 > spans > 38033-45398 > annotations

PMC:7253235 / 38033-45398 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid_Glycan-Motif-Structure

Id Subject Object Predicate Lexical cue
T7 3908-3911 https://glytoucan.org/Structures/Glycans/G00063MO denotes CAD
T8 5313-5316 https://glytoucan.org/Structures/Glycans/G00063MO denotes CAD

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
1324 28-35 Species denotes Patient Tax:9606
1325 43-51 Disease denotes COVID-19 MESH:C000657245
1371 4179-4183 Gene denotes HER2 Gene:2064
1372 4185-4189 Gene denotes BRAF Gene:673
1373 4190-4193 Gene denotes MEK Gene:5609
1374 2186-2193 Species denotes patient Tax:9606
1375 2299-2306 Species denotes patient Tax:9606
1376 2581-2591 Species denotes outpatient Tax:9606
1377 3134-3142 Species denotes patients Tax:9606
1378 3709-3717 Species denotes patients Tax:9606
1379 4106-4114 Species denotes patients Tax:9606
1380 4298-4306 Species denotes Patients Tax:9606
1381 4503-4511 Species denotes patients Tax:9606
1382 4865-4872 Species denotes patient Tax:9606
1383 4899-4907 Species denotes patients Tax:9606
1384 1955-1963 Disease denotes COVID-19 MESH:C000657245
1385 1992-1998 Disease denotes cancer MESH:D009369
1386 2159-2165 Disease denotes cancer MESH:D009369
1387 2214-2222 Disease denotes COVID-19 MESH:C000657245
1388 2225-2231 Disease denotes Cancer MESH:D009369
1389 2447-2455 Disease denotes COVID-19 MESH:C000657245
1390 2560-2566 Disease denotes cancer MESH:D009369
1391 2704-2710 Disease denotes cancer MESH:D009369
1392 2835-2843 Disease denotes COVID-19 MESH:C000657245
1393 3044-3049 Disease denotes tumor MESH:D009369
1394 3264-3278 Disease denotes Cardiotoxicity MESH:D066126
1395 3298-3304 Disease denotes cancer MESH:D009369
1396 3323-3337 Disease denotes cardiomyopathy MESH:D009202
1397 3339-3350 Disease denotes arrhythmias MESH:D001145
1398 3356-3364 Disease denotes ischemic MESH:D007511
1399 3392-3398 Disease denotes cancer MESH:D009369
1400 3452-3460 Disease denotes COVID-19 MESH:C000657245
1401 3474-3492 Disease denotes cardiac and cancer MESH:D006338
1402 3517-3526 Disease denotes mortality MESH:D003643
1403 3768-3771 Disease denotes CVD MESH:D002318
1404 3826-3838 Disease denotes dyslipidemia MESH:D050171
1405 3913-3924 Disease denotes arrhythmias MESH:D001145
1406 3929-3932 Disease denotes CHF
1407 4056-4082 Disease denotes arrhythmias Cardiotoxicity MESH:D066126
1408 4099-4105 Disease denotes cancer MESH:D009369
1409 4149-4155 Disease denotes cancer MESH:D009369
1410 4318-4332 Disease denotes cardiotoxicity MESH:D066126
1411 4384-4398 Disease denotes cardiotoxicity MESH:D066126
1412 4620-4634 Disease denotes cardiotoxicity MESH:D066126
1413 4813-4825 Disease denotes dyslipidemia MESH:D050171
1414 5016-5019 Disease denotes CHF
1415 5052-5058 Disease denotes cancer MESH:D009369
1418 1826-1833 Species denotes patient Tax:9606
1419 1845-1853 Disease denotes COVID-19 MESH:C000657245
1423 5285-5311 Disease denotes CVD cardiovascular disease MESH:D002318
1424 5313-5340 Disease denotes CAD coronary artery disease MESH:D003324
1425 5342-5370 Disease denotes CHF congestive heart failure MESH:D006333
1443 1372-1397 Gene denotes chimeric antigen receptor Gene:9970
1444 130-137 Species denotes patient Tax:9606
1445 294-302 Species denotes patients Tax:9606
1446 503-511 Species denotes patients Tax:9606
1447 684-691 Species denotes patient Tax:9606
1448 879-886 Species denotes patient Tax:9606
1449 1656-1664 Species denotes patients Tax:9606
1450 60-68 Disease denotes COVID-19 MESH:C000657245
1451 287-293 Disease denotes cancer MESH:D009369
1452 323-329 Disease denotes cancer MESH:D009369
1453 430-438 Disease denotes COVID-19 MESH:C000657245
1454 517-523 Disease denotes cancer MESH:D009369
1455 553-561 Disease denotes COVID-19 MESH:C000657245
1456 562-571 Disease denotes infection MESH:D007239
1457 605-611 Disease denotes Cancer MESH:D009369
1458 1438-1446 Disease denotes COVID-19 MESH:C000657245
1459 1637-1643 Disease denotes cancer MESH:D009369
1468 5543-5551 Species denotes patients Tax:9606
1469 5782-5790 Species denotes patients Tax:9606
1470 5886-5896 Species denotes outpatient Tax:9606
1471 5960-5971 Chemical denotes cholesterol MESH:D002784
1472 5646-5658 Disease denotes hypertension MESH:D006973
1473 5679-5703 Disease denotes congestive heart failure MESH:D006333
1474 5879-5885 Disease denotes cancer MESH:D009369
1475 6130-6136 Disease denotes cancer MESH:D009369
1495 7230-7234 Gene denotes HER2 Gene:2064
1496 7259-7263 Gene denotes BRAF Gene:673
1497 7264-7267 Gene denotes MEK Gene:5609
1498 6602-6610 Species denotes patients Tax:9606
1499 6664-6672 Species denotes patients Tax:9606
1500 6895-6903 Species denotes patients Tax:9606
1501 7043-7051 Species denotes patients Tax:9606
1502 7335-7342 Species denotes patient Tax:9606
1503 7243-7257 Chemical denotes anthracyclines MESH:D018943
1504 6185-6199 Disease denotes cardiotoxicity MESH:D066126
1505 6219-6225 Disease denotes cancer MESH:D009369
1506 6417-6431 Disease denotes cardiomyopathy MESH:D009202
1507 6433-6441 Disease denotes ischemia MESH:D007511
1508 6464-6475 Disease denotes arrhythmias MESH:D001145
1509 6513-6528 Disease denotes COVID infection MESH:C000657245
1510 6699-6710 Disease denotes arrhythmias MESH:D001145
1511 6845-6864 Disease denotes pericardial disease MESH:D008476
1512 6927-6941 Disease denotes cardiotoxicity MESH:D066126
1513 7067-7081 Disease denotes cardiotoxicity MESH:D066126

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T113 481-495 Body_part denotes immune systems http://purl.org/sig/ont/fma/fma9825
T114 1340-1351 Body_part denotes bone marrow http://purl.org/sig/ont/fma/fma9608
T115 1705-1718 Body_part denotes immune system http://purl.org/sig/ont/fma/fma9825
T116 2133-2147 Body_part denotes immune systems http://purl.org/sig/ont/fma/fma9825
T117 2999-3012 Body_part denotes immune system http://purl.org/sig/ont/fma/fma9825
T118 4927-4931 Body_part denotes face http://purl.org/sig/ont/fma/fma24728
T119 4935-4939 Body_part denotes face http://purl.org/sig/ont/fma/fma24728
T120 4977-4982 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670
T121 4992-4997 Body_part denotes lipid http://purl.org/sig/ont/fma/fma67264
T122 5156-5167 Body_part denotes bone marrow http://purl.org/sig/ont/fma/fma9608
T123 5317-5332 Body_part denotes coronary artery http://purl.org/sig/ont/fma/fma49893
T124 5357-5362 Body_part denotes heart http://purl.org/sig/ont/fma/fma7088
T125 5690-5695 Body_part denotes heart http://purl.org/sig/ont/fma/fma7088
T126 5735-5739 Body_part denotes face http://purl.org/sig/ont/fma/fma24728
T127 5743-5747 Body_part denotes face http://purl.org/sig/ont/fma/fma24728
T128 6078-6083 Body_part denotes blood http://purl.org/sig/ont/fma/fma9670

LitCovid-PD-UBERON

Id Subject Object Predicate Lexical cue uberon_id
T50 481-495 Body_part denotes immune systems http://purl.obolibrary.org/obo/UBERON_0002405
T51 1340-1351 Body_part denotes bone marrow http://purl.obolibrary.org/obo/UBERON_0002371
T52 1705-1718 Body_part denotes immune system http://purl.obolibrary.org/obo/UBERON_0002405
T53 2133-2147 Body_part denotes immune systems http://purl.obolibrary.org/obo/UBERON_0002405
T54 2999-3012 Body_part denotes immune system http://purl.obolibrary.org/obo/UBERON_0002405
T55 4927-4931 Body_part denotes face http://purl.obolibrary.org/obo/UBERON_0001456
T56 4935-4939 Body_part denotes face http://purl.obolibrary.org/obo/UBERON_0001456
T57 4977-4982 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178
T58 5156-5167 Body_part denotes bone marrow http://purl.obolibrary.org/obo/UBERON_0002371
T59 5317-5332 Body_part denotes coronary artery http://purl.obolibrary.org/obo/UBERON_0001621
T60 5326-5332 Body_part denotes artery http://purl.obolibrary.org/obo/UBERON_0001637
T61 5357-5362 Body_part denotes heart http://purl.obolibrary.org/obo/UBERON_0000948
T62 5690-5695 Body_part denotes heart http://purl.obolibrary.org/obo/UBERON_0000948
T63 5735-5739 Body_part denotes face http://purl.obolibrary.org/obo/UBERON_0001456
T64 5743-5747 Body_part denotes face http://purl.obolibrary.org/obo/UBERON_0001456
T65 6078-6083 Body_part denotes blood http://purl.obolibrary.org/obo/UBERON_0000178

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T387 43-51 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T388 60-68 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T389 287-293 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T390 323-329 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T391 430-438 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T392 517-523 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T393 553-561 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T394 562-571 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T395 605-611 Disease denotes Cancer http://purl.obolibrary.org/obo/MONDO_0004992
T396 1438-1446 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T397 1637-1643 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T398 1845-1853 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T399 1955-1963 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T400 1992-1998 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T401 2159-2165 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T402 2214-2222 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T403 2225-2231 Disease denotes Cancer http://purl.obolibrary.org/obo/MONDO_0004992
T404 2447-2455 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T405 2560-2566 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T406 2704-2710 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T407 2835-2843 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T408 3044-3049 Disease denotes tumor http://purl.obolibrary.org/obo/MONDO_0005070
T409 3298-3304 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T410 3323-3337 Disease denotes cardiomyopathy http://purl.obolibrary.org/obo/MONDO_0004994
T411 3339-3350 Disease denotes arrhythmias http://purl.obolibrary.org/obo/MONDO_0007263
T412 3392-3398 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T413 3452-3460 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T414 3486-3492 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T415 3815-3818 Disease denotes HTN http://purl.obolibrary.org/obo/MONDO_0005044
T416 3826-3838 Disease denotes dyslipidemia http://purl.obolibrary.org/obo/MONDO_0002525
T417 3908-3911 Disease denotes CAD http://purl.obolibrary.org/obo/MONDO_0005010|http://purl.obolibrary.org/obo/MONDO_0018922
T419 3913-3924 Disease denotes arrhythmias http://purl.obolibrary.org/obo/MONDO_0007263
T420 3929-3932 Disease denotes CHF http://purl.obolibrary.org/obo/MONDO_0005009
T421 4056-4067 Disease denotes arrhythmias http://purl.obolibrary.org/obo/MONDO_0007263
T422 4099-4105 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T423 4149-4155 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T424 4813-4825 Disease denotes dyslipidemia http://purl.obolibrary.org/obo/MONDO_0002525
T425 5016-5019 Disease denotes CHF http://purl.obolibrary.org/obo/MONDO_0005009
T426 5052-5058 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T427 5289-5311 Disease denotes cardiovascular disease http://purl.obolibrary.org/obo/MONDO_0004995
T428 5313-5316 Disease denotes CAD http://purl.obolibrary.org/obo/MONDO_0005010|http://purl.obolibrary.org/obo/MONDO_0018922
T430 5317-5340 Disease denotes coronary artery disease http://purl.obolibrary.org/obo/MONDO_0005010
T431 5326-5340 Disease denotes artery disease http://purl.obolibrary.org/obo/MONDO_0000473
T432 5342-5345 Disease denotes CHF http://purl.obolibrary.org/obo/MONDO_0005009
T433 5346-5370 Disease denotes congestive heart failure http://purl.obolibrary.org/obo/MONDO_0005009
T434 5357-5370 Disease denotes heart failure http://purl.obolibrary.org/obo/MONDO_0005252
T435 5646-5658 Disease denotes hypertension http://purl.obolibrary.org/obo/MONDO_0005044
T436 5679-5703 Disease denotes congestive heart failure http://purl.obolibrary.org/obo/MONDO_0005009
T437 5690-5703 Disease denotes heart failure http://purl.obolibrary.org/obo/MONDO_0005252
T438 5879-5885 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T439 6130-6136 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T440 6219-6225 Disease denotes cancer http://purl.obolibrary.org/obo/MONDO_0004992
T441 6417-6431 Disease denotes cardiomyopathy http://purl.obolibrary.org/obo/MONDO_0004994
T442 6433-6441 Disease denotes ischemia http://purl.obolibrary.org/obo/MONDO_0005053
T443 6464-6475 Disease denotes arrhythmias http://purl.obolibrary.org/obo/MONDO_0007263
T444 6519-6528 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T445 6699-6710 Disease denotes arrhythmias http://purl.obolibrary.org/obo/MONDO_0007263

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T296 78-81 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T297 88-89 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T298 481-495 http://purl.obolibrary.org/obo/UBERON_0002405 denotes immune systems
T299 826-833 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T300 980-982 http://purl.obolibrary.org/obo/CLO_0001382 denotes 48
T301 1340-1344 http://purl.obolibrary.org/obo/UBERON_0002481 denotes bone
T302 1461-1468 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T303 1705-1718 http://purl.obolibrary.org/obo/UBERON_0002405 denotes immune system
T304 2071-2074 http://purl.obolibrary.org/obo/CLO_0002199 denotes CAR
T305 2133-2147 http://purl.obolibrary.org/obo/UBERON_0002405 denotes immune systems
T306 2456-2463 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T307 2823-2830 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T308 2999-3012 http://purl.obolibrary.org/obo/UBERON_0002405 denotes immune system
T309 3549-3556 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T310 4673-4680 http://purl.obolibrary.org/obo/UBERON_0000473 denotes testing
T311 4927-4931 http://purl.obolibrary.org/obo/UBERON_0001456 denotes face
T312 4935-4939 http://purl.obolibrary.org/obo/UBERON_0001456 denotes face
T313 4977-4982 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T314 4977-4982 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T315 5156-5160 http://purl.obolibrary.org/obo/UBERON_0002481 denotes bone
T316 5185-5188 http://purl.obolibrary.org/obo/CLO_0002199 denotes CAR
T317 5326-5332 http://purl.obolibrary.org/obo/UBERON_0001637 denotes artery
T318 5326-5332 http://www.ebi.ac.uk/efo/EFO_0000814 denotes artery
T319 5357-5362 http://purl.obolibrary.org/obo/UBERON_0000948 denotes heart
T320 5357-5362 http://purl.obolibrary.org/obo/UBERON_0007100 denotes heart
T321 5357-5362 http://purl.obolibrary.org/obo/UBERON_0015228 denotes heart
T322 5357-5362 http://www.ebi.ac.uk/efo/EFO_0000815 denotes heart
T323 5690-5695 http://purl.obolibrary.org/obo/UBERON_0000948 denotes heart
T324 5690-5695 http://purl.obolibrary.org/obo/UBERON_0007100 denotes heart
T325 5690-5695 http://purl.obolibrary.org/obo/UBERON_0015228 denotes heart
T326 5690-5695 http://www.ebi.ac.uk/efo/EFO_0000815 denotes heart
T327 5733-5734 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T328 5735-5739 http://purl.obolibrary.org/obo/UBERON_0001456 denotes face
T329 5743-5747 http://purl.obolibrary.org/obo/UBERON_0001456 denotes face
T330 6078-6083 http://purl.obolibrary.org/obo/UBERON_0000178 denotes blood
T331 6078-6083 http://www.ebi.ac.uk/efo/EFO_0000296 denotes blood
T332 6251-6252 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T333 6801-6808 http://purl.obolibrary.org/obo/CLO_0009985 denotes focused

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T113 1381-1388 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T114 1601-1609 Chemical denotes carriers http://purl.obolibrary.org/obo/CHEBI_78059
T115 2323-2331 Chemical denotes carriers http://purl.obolibrary.org/obo/CHEBI_78059
T116 3600-3608 Chemical denotes carriers http://purl.obolibrary.org/obo/CHEBI_78059
T117 4190-4193 Chemical denotes MEK http://purl.obolibrary.org/obo/CHEBI_28398
T118 4406-4420 Chemical denotes anthracyclines http://purl.obolibrary.org/obo/CHEBI_48120|http://purl.obolibrary.org/obo/CHEBI_49322
T120 4992-4997 Chemical denotes lipid http://purl.obolibrary.org/obo/CHEBI_18059
T121 5200-5207 Chemical denotes antigen http://purl.obolibrary.org/obo/CHEBI_59132
T122 5960-5971 Chemical denotes cholesterol http://purl.obolibrary.org/obo/CHEBI_16113
T123 7243-7257 Chemical denotes anthracyclines http://purl.obolibrary.org/obo/CHEBI_48120|http://purl.obolibrary.org/obo/CHEBI_49322
T125 7264-7267 Chemical denotes MEK http://purl.obolibrary.org/obo/CHEBI_28398

LitCovid-PD-GO-BP

Id Subject Object Predicate Lexical cue
T28 4004-4010 http://purl.obolibrary.org/obo/GO_0048511 denotes rhythm
T29 6644-6650 http://purl.obolibrary.org/obo/GO_0048511 denotes rhythm

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T208 19-27 Phenotype denotes Oncology http://purl.obolibrary.org/obo/HP_0002664
T209 287-293 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T210 323-329 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T211 517-523 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T212 605-611 Phenotype denotes Cancer http://purl.obolibrary.org/obo/HP_0002664
T213 1134-1142 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T214 1637-1643 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T215 1817-1825 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T216 1870-1878 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T217 1992-1998 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T218 2159-2165 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T219 2225-2231 Phenotype denotes Cancer http://purl.obolibrary.org/obo/HP_0002664
T220 2560-2566 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T221 2704-2710 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T222 2888-2896 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T223 2897-2905 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T224 3044-3049 Phenotype denotes tumor http://purl.obolibrary.org/obo/HP_0002664
T225 3298-3304 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T226 3323-3337 Phenotype denotes cardiomyopathy http://purl.obolibrary.org/obo/HP_0001638
T227 3339-3350 Phenotype denotes arrhythmias http://purl.obolibrary.org/obo/HP_0011675
T228 3392-3398 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T229 3421-3429 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T230 3486-3492 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T231 3826-3838 Phenotype denotes dyslipidemia http://purl.obolibrary.org/obo/HP_0003119
T232 3913-3924 Phenotype denotes arrhythmias http://purl.obolibrary.org/obo/HP_0011675
T233 3929-3932 Phenotype denotes CHF http://purl.obolibrary.org/obo/HP_0001635
T234 4056-4067 Phenotype denotes arrhythmias http://purl.obolibrary.org/obo/HP_0011675
T235 4099-4105 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T236 4149-4155 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T237 4813-4825 Phenotype denotes dyslipidemia http://purl.obolibrary.org/obo/HP_0003119
T238 5016-5019 Phenotype denotes CHF http://purl.obolibrary.org/obo/HP_0001635
T239 5052-5058 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T240 5289-5311 Phenotype denotes cardiovascular disease http://purl.obolibrary.org/obo/HP_0001626
T241 5342-5345 Phenotype denotes CHF http://purl.obolibrary.org/obo/HP_0001635
T242 5346-5370 Phenotype denotes congestive heart failure http://purl.obolibrary.org/obo/HP_0001635
T243 5646-5658 Phenotype denotes hypertension http://purl.obolibrary.org/obo/HP_0000822
T244 5679-5703 Phenotype denotes congestive heart failure http://purl.obolibrary.org/obo/HP_0001635
T245 5826-5834 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664
T246 5879-5885 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T247 6130-6136 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T248 6219-6225 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T249 6417-6431 Phenotype denotes cardiomyopathy http://purl.obolibrary.org/obo/HP_0001638
T250 6464-6475 Phenotype denotes arrhythmias http://purl.obolibrary.org/obo/HP_0011675
T251 6699-6710 Phenotype denotes arrhythmias http://purl.obolibrary.org/obo/HP_0011675
T252 7319-7327 Phenotype denotes oncology http://purl.obolibrary.org/obo/HP_0002664

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T240 0-55 Sentence denotes Care of the Cardio-Oncology Patient in the COVID-19 Era
T241 56-311 Sentence denotes The COVID-19 pandemic has added a significant layer and complexity of how patient care is being delivered due to concerns of bidirectional transmission, with no protective algorithm widely in place to dictate ongoing management of cancer patients [108••].
T242 312-443 Sentence denotes Initiating cancer treatments, such as targeted immunotherapies and chemotherapy, require special consideration in the COVID-19 era.
T243 444-604 Sentence denotes As previously described, compromised immune systems render patients with cancer at higher risk for acquiring COVID-19 infection and the sequelae that may ensue.
T244 605-788 Sentence denotes Cancer treatment centers and cardio-oncologists must now consider not only the patient but also the integral healthcare workers who are regularly interfacing with high-risk exposures.
T245 789-994 Sentence denotes Devising strategies to ensure robust testing services and clearance mechanisms to protect patient and healthcare personnel is one of many methods now employed to continue ongoing treatments [48, 109, 110].
T246 995-1191 Sentence denotes Though there are no clear evidence-based modifications in systems of care to reduce transmission risk while balancing high-standard cardio-oncology care, various strategies are proposed (Table 2).
T247 1192-1437 Sentence denotes Life-prolonging surgeries and procedures can slowly be pursued and continued, although the risks of delaying any such advanced treatments—including bone marrow transplantation and chimeric antigen receptor treatment—need to be weighed carefully.
T248 1438-1610 Sentence denotes COVID-19 screening and testing prior to these surgeries/procedures, while not infallible, should be considered if available due to rising concern for asymptomatic carriers.
T249 1611-1762 Sentence denotes Following completing anti-cancer treatments, patients may additionally benefit from receiving immune system restorative treatments, such as filgastrim.
T250 1763-1862 Sentence denotes Table 2 Proposed special considerations of the cardio-oncology patient during the COVID-19 pandemic
T251 1863-1972 Sentence denotes Cardio-oncology aspect of care Theoretical areas of concern Proposed Strategies to Mitigate COVID-19 Exposure
T252 1973-2222 Sentence denotes Initiating/ongoing cancer treatments (i.e., chemotherapy, targeted therapies, immunotherapy, BMT, CAR-T), and timing of oncologic-related surgery • Compromised immune systems induced by cancer treatments may make patient more susceptible to COVID-19
T253 2223-2343 Sentence denotes • Cancer treatments may require healthcare facility/inpatient stay exposing patient to asymptomatic carriers (i.e., HCW)
T254 2344-2435 Sentence denotes • Delaying of potential critical, life-prolonging surgery as it may be deemed as “elective”
T255 2436-2646 Sentence denotes • Ensuring COVID-19 testing adequacy by healthcare providers • Implementation of universal PPE and social distancing during cancer treatments in outpatient/inpatient settings, and with family members/caretakers
T256 2647-2782 Sentence denotes • Weighing risk-benefit of postponing/delaying timing of cancer treatments/surgery to minimize exposure to inpatient healthcare setting
T257 2783-2843 Sentence denotes • Preoperative/procedural screening and testing for COVID-19
T258 2844-2942 Sentence denotes • Telemedicine for routine follow-up cardio-oncology/oncology visits unless clinically symptomatic
T259 2943-3057 Sentence denotes • Research efforts investigating earlier utilization of immune system restorative measures post anti-tumor therapy
T260 3058-3176 Sentence denotes • Consideration of delaying myeloablative therapies and immunotherapies for patients in clinical remission if possible
T261 3177-3263 Sentence denotes • Consideration of minimizing surveillance/staging imaging during and after treatments
T262 3264-3526 Sentence denotes Cardiotoxicity experienced during cancer treatments (i.e., cardiomyopathy, arrhythmias, and ischemic events) • Further delay of cancer treatments and cardio-oncology evaluation because of COVID-19 may increase cardiac and cancer-related comorbidity and mortality
T263 3527-3689 Sentence denotes • Cardiac imaging and testing may cause further exposure to asymptomatic carriers • Inpatient admission and evaluation as clinically indicated for severe symptoms
T264 3690-3839 Sentence denotes • Telemedicine for patients who are asymptomatic or minimally symptomatic, or CVD risk factor modification (i.e., visits for HTN and/or dyslipidemia)
T265 3840-3985 Sentence denotes • Preemptive aggressive treatment for suspected symptoms related to CAD, arrhythmias, or CHF and deferring of imaging unless clinically necessary
T266 3986-4067 Sentence denotes • Mail ambulatory rhythm monitors to home to evaluate suspected/known arrhythmias
T267 4068-4295 Sentence denotes Cardiotoxicity surveillance in cancer patients during and after treatment • Some cancer treatments (i.e., anti-HER2, BRAF-MEK treatments, clinical trials) require frequent surveillance of cardiac function (i.e., every 3 months)
T268 4296-4531 Sentence denotes • Patients with known cardiotoxicity, or with known treatments that can cause long-term cardiotoxicity (i.e., anthracyclines, radiation) may not get timely surveillance imaging • Minimize cardiac imaging to patients who are symptomatic
T269 4532-4693 Sentence denotes • Multidisciplinary discussion with hematologist/oncologist about reducing frequency of cardiotoxicity screening, especially if prior serial testing unremarkable
T270 4694-4767 Sentence denotes • Limited imaging protocols to evaluate LVEF to minimize acquisition time
T271 4768-4872 Sentence denotes • Defer primary prevention assessment (i.e., dyslipidemia management) unless critical to care of patient
T272 4873-5020 Sentence denotes • Telemedicine visits for patients who do not require face-to-face assessment for medical issues (i.e., blood pressure/lipid management/stable CHF)
T273 5021-5151 Sentence denotes • Defer asymptomatic long-term cancer survivor surveillance (i.e., assessment of ventricular and valvular function) if no symptoms
T274 5152-5411 Sentence denotes BMT bone marrow transplantation, CAR-T chimeric antigen receptor therapy, HCW healthcare workers, PPE personal protective equipment, CVD cardiovascular disease, CAD coronary artery disease, CHF congestive heart failure, LVEF left ventricular ejection fraction
T275 5412-5611 Sentence denotes Additionally, the transition to telemedicine to conduct interval cardiovascular and oncologic appointments can potentially protect patients from unnecessarily harmful nosocomial exposures [111, 112].
T276 5612-5904 Sentence denotes Certain chronic conditions (i.e., hypertension, stable/compensated congestive heart failure) may not necessarily require a face-to-face visit, whereas highly symptomatic patients should still be seen in the cardio-oncology clinic, preferably on the same day as their cancer outpatient visits.
T277 5905-6054 Sentence denotes Deferring primary prevention assessments, for example, cholesterol monitoring, unless otherwise indicated can augment protective mechanisms in place.
T278 6055-6156 Sentence denotes Cardiovascular-related blood draws, if necessary, should be coincided with cancer-related treatments.
T279 6157-6368 Sentence denotes In addition, the specter of cardiotoxicity related to certain cancer treatments also requires a reexamination of risk and benefit with respect to frequent cardiac monitoring due to previously mentioned concerns.
T280 6369-6529 Sentence denotes Peri-chemotherapeutic events and development of cardiomyopathy, ischemia, and life-threatening arrhythmias are further worsened by simultaneous COVID infection.
T281 6530-6759 Sentence denotes Reducing reliance on frequent cardiac imaging in otherwise asymptomatic patients and providing in-mail ambulatory rhythm monitors for patients symptomatic with possible arrhythmias will further assist in mitigating exposure risk.
T282 6760-7025 Sentence denotes Limited cardiac-imaging protocols (i.e., focused just on ventricular function and/or pericardial disease) if necessary for symptomatic patients or those necessitating cardiotoxicity surveillance can also be devised to reduce exposure time in the healthcare setting.
T283 7026-7365 Sentence denotes In addition, for patients at low risk of cardiotoxicity and/or with prior serial-documented normal cardiac function, it can be considered to defer serial cardiac imaging in certain treatments (i.e., anti-HER2 without anthracyclines, BRAF-MEK treatments), in multidisciplinary discussions with oncology if the patient is asymptomatic [113].

2_test

Id Subject Object Predicate Lexical cue
32462289-32343498-24381001 989-992 32343498 denotes 110
32462289-32160451-24381002 5606-5609 32160451 denotes 112
32462289-32087998-24381003 7360-7363 32087998 denotes 113